- Home
- GLBE vs MDGL Comparison
GLBE vs MDGL Comparison
Compare GLBE & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLBE
- MDGL
- Stock Information
- Founded
- GLBE 2013
- MDGL 2011
- Country
- GLBE Israel
- MDGL United States
- Employees
- GLBE N/A
- MDGL N/A
- Industry
- GLBE Computer Software: Prepackaged Software
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- GLBE Technology
- MDGL Health Care
- Exchange
- GLBE Nasdaq
- MDGL Nasdaq
- Market Cap
- GLBE 6.1B
- MDGL 6.8B
- IPO Year
- GLBE 2021
- MDGL N/A
- Fundamental
- Price
- GLBE $37.83
- MDGL $294.64
- Analyst Decision
- GLBE Strong Buy
- MDGL Strong Buy
- Analyst Count
- GLBE 13
- MDGL 10
- Target Price
- GLBE $52.38
- MDGL $420.63
- AVG Volume (30 Days)
- GLBE 1.5M
- MDGL 373.7K
- Earning Date
- GLBE 05-14-2025
- MDGL 05-01-2025
- Dividend Yield
- GLBE N/A
- MDGL N/A
- EPS Growth
- GLBE N/A
- MDGL N/A
- EPS
- GLBE N/A
- MDGL N/A
- Revenue
- GLBE $752,764,000.00
- MDGL $317,383,000.00
- Revenue This Year
- GLBE $26.08
- MDGL $230.69
- Revenue Next Year
- GLBE $24.96
- MDGL $74.76
- P/E Ratio
- GLBE N/A
- MDGL N/A
- Revenue Growth
- GLBE 32.08
- MDGL N/A
- 52 Week Low
- GLBE $26.64
- MDGL $200.08
- 52 Week High
- GLBE $63.69
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- GLBE 58.91
- MDGL 39.29
- Support Level
- GLBE $35.68
- MDGL $287.46
- Resistance Level
- GLBE $37.24
- MDGL $349.00
- Average True Range (ATR)
- GLBE 1.30
- MDGL 17.20
- MACD
- GLBE 0.57
- MDGL -2.36
- Stochastic Oscillator
- GLBE 93.42
- MDGL 11.67
About GLBE Global-E Online Ltd.
Global E Online Ltd provides e-commerce solutions. The company offers a platform to enable and accelerate direct-to-consumer cross-border e-commerce. The platform was purpose-built for international shoppers to buy seamlessly online and for merchants to sell from and anywhere in the world. The company localizes the shopper experience to make international transactions as seamless as domestic ones. The platform increases the conversion of international traffic into sales by removing much of the complexity associated with international e-commerce. The company derives maximum revenue from the United States.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.